Vogliviga GM1/0.3 Tablet in PCD pharma franchise in Hyderabad

Vogliviga GM1/0.3 Tablet in pharmaceutical manufacturing company in Mumbai

Vogliviga GM1/0.3 Tablet in diabetic pharma franchise in Pune

Vogliviga GM1/0.3 Tablet in pharma suppliers in Delhi

Vogliviga GM1/0.3 Tablet in pharma export companies in Kolkata
Vogliviga GM1/0.3 Tablet in pharma franchise opportunities in Bengaluru

Home/Products /glimepiride-1mg-voglibose-3mg-metformin-hcl-layered-tablets

Vogliviga GM1-0.3 Tablet

Composition : Glimepiride I.P. 1mg + Voglibose I.P. 0.3mg + Metformin HCL I.P. 500mg Bi-Layered Tablets

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*15

Price : ₹189/-

Vogliviga GM1/0.3 Tablet contains Glimepiride 1mg, Voglibose 0.3mg, and Metformin 500mg in a bi-layered formulation to effectively manage type 2 diabetes mellitus. Glimepiride promotes insulin secretion, Voglibose helps reduce post-meal blood sugar spikes by slowing carbohydrate absorption, and Metformin improves insulin sensitivity while decreasing hepatic glucose production. This combination ensures comprehensive blood sugar control throughout the day.

Read More

About the Product

Vogliviga GM1/0.3 Tablet contains Glimepiride 1mg, Voglibose 0.3mg, and Metformin 500mg in a bi-layered formulation to effectively manage type 2 diabetes mellitus. Glimepiride promotes insulin secretion, Voglibose helps reduce post-meal blood sugar spikes by slowing carbohydrate absorption, and Metformin improves insulin sensitivity while decreasing hepatic glucose production. This combination ensures comprehensive blood sugar control throughout the day.

Possible side effects include nausea, abdominal discomfort, bloating, diarrhea, and risk of hypoglycemia. Long-term use may lead to vitamin B12 deficiency. Patients should monitor blood glucose regularly.

It is prescribed for the treatment of type 2 diabetes, particularly for patients needing control of both fasting and postprandial glucose levels.

Not recommended for patients with type 1 diabetes, severe kidney or liver impairment, or diabetic ketoacidosis. Alcohol should be avoided during treatment. Follow medical advice strictly and report any unusual symptoms.

Store in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation